Synthetic Lethality & Cancer Therapy

The genetic concept of synthetic lethality, in which the combination or synthesis of mutations in multiple genes results in cell death, provides a framework to design novel therapeutic approaches to cancer. Discover the latest research on synthetic lethality and cancer therapy here.

January 21, 2021

[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].

Gan to kagaku ryoho. Cancer & chemotherapy
Yuko TsunodaEisuke Fukuma
January 11, 2021
Open Access

Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age

Trends in Pharmacological Sciences
Dexter Kai Hao ThngEdward Kai-Hua Chow
January 16, 2021
Open Access

CRISPR base editing applications for identifying cancer-driving mutations

Biochemical Society Transactions
Martin Pal, Marco J Herold
January 12, 2021
Open Access

Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1

The Journal of Biological Chemistry
Kevin RyanKetan S Gajiwala
January 10, 2021
Open Access

Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials

Journal of Clinical Pharmacy and Therapeutics
Chengyuan Wang, Jing Li
January 15, 2021
Open Access

Reshaping the Gut Microbiome in An Apc-Mutant Genetic Background: Mechanistic Insights From Integrated Multi-Omics

Ying-Shiuan ChenRoderick Dashwood
January 11, 2021
Open Access

Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma

BioRxiv : the Preprint Server for Biology
G. WilliamsMarco Loddo
January 15, 2021
Open Access

Integrating PARP inhibitors into the management of breast cancer: where are we?

Chinese Clinical Oncology
Hamdy A AzimHatem Azim
January 23, 2021
Open Access

Fluorescent detection of PARP activity in unfixed tissue.

PloS One
Soumaya BelhadjFrançois Paquet-Durand
January 15, 2021
Open Access

High-resolution characterization of gene function using single-cell CRISPR tiling screen

Lu YangChun-Wei Chen
January 12, 2021
Open Access

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

Therapeutic Advances in Medical Oncology
Reem AliSrinivasan Madhusudan
January 13, 2021

A robust platform for expansion and genome editing of primary human natural killer cells

The Journal of Experimental Medicine
Rih-Sheng HuangSteven Lin
January 20, 2021

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells

Nature Cell Biology
Priyanka VermaRoger A Greenberg
January 20, 2021

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Tamara L LotanEmmanuel S Antonarakis
January 22, 2021

Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020.

The Cancer Journal
Lauren C BrownSherene Loi
January 10, 2021
Open Access

Genomic Landscapes of Acral Melanomas in East Asia

Cancer Genomics & Proteomics
John Wen-Cheng ChangJason Yongsheng Chan
January 16, 2021

Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1

Journal of Zhejiang University. Science. B
Fan Zhang, Zihua Gong

Sign up to follow this feed and discover related papers.

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Cancer Cell Invasion: Nanomedicine

Nanomedicine is a promising alternative for cancer detection and therapy that utilizes nanoparticles, such as liposomes. Nanoparticles can potentially target cancer cell invasion and metastasis. Discover the latest research on Cancer Cell Invasion: Nanomedicine here.

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

© 2021 Meta ULC. All rights reserved